6. Pulmonary Embolism (Massive / High-Risk PE)

Quick Recap

Nests under Acute Respiratory Failure / Obstructive Shock. Updated with the first-ever AHA/ACC Acute PE Guideline (Creager et al., approved by ACC/AHA Oct 2025, published JACC/Circulation Feb 19, 2026) alongside the established ESC 2019 framework.

1. Definition

Acute PE = obstruction of the pulmonary arterial circulation by thrombus (typically originating from deep venous thrombosis), causing acute right ventricular pressure overload, impaired gas exchange, and (in severe cases) obstructive shock.

2. Classification

A. AHA/ACC Acute PE Clinical Categories (2026 guideline — new standard)

The first joint AHA/ACC PE guideline replaces the older massive/submassive/non-massive terminology with a 5-tier A-E system with subcategories, designed to better link severity to disposition and therapy:

Respiratory modifier "R": appended to the category when respiratory failure criteria are met (e.g., C3R, D2R) — signals additional severity independent of the hemodynamic/biomarker axis.

Key 2026 guideline recommendations:

• DOACs recommended over VKAs for eligible patients (reduces bleeding, non-inferior efficacy)
• Multidisciplinary PERT assessment recommended for Categories C-E (and consider for A/B with major comorbidities, e.g., Category B with intracranial hemorrhage)
• Category E1: advanced reperfusion (systemic thrombolysis, catheter-directed lysis, mechanical thrombectomy, or surgical embolectomy) recommended
• Category D1-D2: advanced reperfusion should be considered (not automatic)
• Surgical embolectomy may be considered over systemic thrombolysis in D1-E1 surgical candidates specifically to reduce intracranial hemorrhage risk, though comparative benefit on survival/function is unclear
• Surgical embolectomy NOT recommended over anticoagulation alone in Categories A-C3
• Category E2 patients not on mechanical circulatory support: surgical embolectomy not recommended over other advanced therapies for short-term mortality
• Unstable (Category E) patients must NOT be transferred before hemodynamic stabilization
• Post-PE follow-up recommended for >=1 year with symptom/functional assessment at every visit to detect chronic thromboembolic pulmonary disease (CTEPD)/CTEPH, plus attention to depression, anxiety, PTSD, exercise capacity, and travel-related recurrence risk

B. ESC 2019 Risk Stratification (still widely referenced, maps conceptually onto AHA/ACC categories)

4 axes: (1) hemodynamic instability, (2) imaging-detected RV dysfunction (echo or CTPA: RV/LV ratio >1.0, RV free wall hypokinesis, elevated TR jet velocity), (3) elevated PESI/sPESI, (4) elevated cardiac troponin.

Approximate mapping: ESC low/intermediate-low ~ AHA/ACC B-C1; ESC intermediate-high ~ AHA/ACC C2-D; ESC high (massive) ~ AHA/ACC E.

3. Pathophysiology

Thrombus (usually from lower-extremity/pelvic DVT) embolizes to pulmonary arterial circulation -> acute increase in pulmonary vascular resistance -> RV afterload rises abruptly (RV is not adapted to acute pressure load, unlike chronic pulmonary hypertension) -> RV dilation, wall stress, ischemia (McConnell's sign: free wall hypokinesis with apical sparing) -> septal bowing into LV -> reduced LV preload and cardiac output -> systemic hypotension/shock (obstructive shock) -> RV failure causes ~50% of PE deaths in the first 30 days. Concurrent V/Q mismatch and dead-space ventilation cause hypoxemia and hypocapnia (initially) or hypercapnia (if severe).

Epidemiology: ~5-10% of VTE progresses to PE; ~10% of PE cases are hemodynamically significant. Shock in PE -> 5-7x mortality increase. Cardiac arrest presentation -> mortality >65%.

4. Immediate Stabilization (ABCDE)

Airway: secure if in extremis; positive pressure ventilation can worsen RV preload/afterload — use cautiously, minimize PEEP where possible in shock states.

Breathing: supplemental O2 for hypoxemia; avoid unnecessary intubation/high PEEP if possible (increases intrathoracic pressure, further compromises RV preload) — if intubation unavoidable, use lowest effective PEEP and judicious induction agent choice to avoid hemodynamic collapse.

Circulation:

• Do not fluid-overload the failing RV — cautious fluid bolus only (250-500 mL), reassess; excessive fluid worsens RV distension and further compromises LV filling via septal shift
• Vasopressor of choice: norepinephrine (supports RV coronary perfusion pressure and systemic pressure); consider adding dobutamine for inotropic support in low-output states
• Anticoagulation: initiate promptly (unfractionated heparin preferred initially in unstable/high-risk patients for its reversibility) once bleeding risk assessed — do not delay for confirmatory imaging in patients with high clinical probability and acceptable bleeding risk
• Category E (unstable): proceed to advanced reperfusion per Section 2

Disability: assess mental status — syncope/altered consciousness is a high-risk marker (part of modified FAST score).

Exposure: examine for DVT signs (leg swelling/tenderness), recent surgery/immobilization/malignancy history.

Checklist:

5. Focused History

VTE risk factors: recent surgery/hospitalization, trauma, prolonged immobilization, malignancy, pregnancy/postpartum, obesity, hormonal therapy/OCPs, prior VTE, inherited/acquired thrombophilia, indwelling vascular catheters. Symptom onset (dyspnea, pleuritic chest pain, hemoptysis, syncope — syncope suggests high clot burden/hemodynamic compromise). Leg swelling/pain (DVT). Bleeding risk factors (informs anticoagulation/thrombolysis decision).

6. Examination + POCUS

Tachycardia, tachypnea, hypoxemia, signs of DVT, elevated JVP, loud P2, RV heave, hypotension in severe cases.

POCUS/bedside echo (central to risk stratification): RV dilation, RV/LV ratio >1.0, McConnell's sign (RV free wall hypokinesis with apical sparing), septal flattening/"D-sign," reduced TAPSE, elevated TR jet velocity, 60/60 sign (PASP <60 mmHg with pulmonary acceleration time <60 msec) — also rapidly excludes mimics (tamponade, aortic dissection, primary cardiomyopathy). Lower-extremity compression ultrasound for DVT confirmation.

7. Syndrome Identification

Obstructive shock (if Category E) or acute RV pressure-overload syndrome with hypoxemic respiratory failure — distinguish from cardiogenic, distributive, and hypovolemic shock using bedside echo.

8. Differential Diagnosis

9. Severity Assessment

Use AHA/ACC Category (primary, Section 2) alongside supporting tools: PESI/sPESI (clinical severity score), Bova score (SBP 90-100=2pts, troponin elevation=2pts, RV dysfunction=2pts, HR>110=1pt; >4 points = highest risk), modified FAST score (age-adjusted hs-troponin, syncope, HR>=100), Shock Index (HR/SBP; >1.0 = high risk). These refine risk within the AHA/ACC low/intermediate categories.

10. Investigations

• Bedside: ECG (sinus tachycardia most common; S1Q3T3 classic but insensitive; new RBBB), POCUS/bedside echo, ABG
• Labs: D-dimer (high sensitivity/low specificity — use to rule out in low-probability patients per validated pretest probability tools, e.g., Wells/Geneva/PERC), troponin (RV injury marker, prognostic), BNP/NT-proBNP (RV strain marker), CBC, renal function, coagulation panel (baseline before anticoagulation/thrombolysis)
• Definitive imaging: CT pulmonary angiography (CTPA) — first-line; V/Q scan if CTPA contraindicated (renal failure, contrast allergy, pregnancy considerations)
• DVT confirmation: lower-extremity duplex ultrasound
• Do not delay anticoagulation for imaging in high clinical probability with acceptable bleeding risk

11. Evidence-Based Management

Anticoagulation (foundation of therapy for all but Category A observation-only cases):

• Unfractionated heparin IV preferred initially in unstable/high-risk (Category D-E) or if reperfusion therapy anticipated (reversibility)
• LMWH or DOAC-eligible patients: DOACs preferred over VKA per 2026 AHA/ACC guideline (reduced bleeding, non-inferior efficacy) once stabilized/appropriate
• Consider HIT if thrombocytopenia develops on heparin — switch to argatroban/bivalirudin, avoid all heparin/warfarin until resolved

Reperfusion therapy (Category-guided, Section 2):

• Category E1: systemic thrombolysis (alteplase), catheter-directed lysis, mechanical thrombectomy, or surgical embolectomy — recommended
• Category D1-D2: consider advanced therapy on a case-by-case basis via PERT
• Category A-C3: anticoagulation alone; surgical embolectomy not recommended over anticoagulation
• Half-dose tPA has shown reduced post-PE pulmonary hypertension in "moderately severe" PE (MOPETT-type evidence); combined thrombolysis + anticoagulation reduces all-cause mortality vs anticoagulation alone but increases major bleeding risk (significant mainly in patients >65 years)
• Catheter-directed intervention (CDI) reasonable for intermediate-high-risk/Category C3-D patients at risk of deterioration
• ECMO: consider for severe shock/refractory instability — observational data suggest ~70% survival regardless of concurrent definitive PE treatment; no RCT evidence yet

IVC filter: consider in patients with contraindication to anticoagulation, or marginal cardiac reserve with high residual clot burden and ongoing embolization risk.

12. Organ Support

Cautious fluid management (RV-protective), norepinephrine +/- dobutamine for shock, lowest-tolerable PEEP if ventilated, ECMO as bridge/rescue in refractory shock (Section 11), standard ICU supportive care.

13. Consultation Matrix

14. Monitoring Framework

Continuous hemodynamic monitoring, serial troponin/lactate trend in unstable patients, repeat bedside echo to track RV recovery, watch for bleeding complications post-anticoagulation/thrombolysis, monitor for recurrent embolization signs.

15. ICU Bundle Checklist (Daily)

16. Complications

RV failure/cardiogenic-obstructive shock, cardiac arrest (PEA arrest classically from acute RV failure), bleeding (anticoagulation/thrombolysis-related, including intracranial hemorrhage — a key driver of therapy selection in Category D-E), recurrent VTE, post-PE syndrome, chronic thromboembolic pulmonary hypertension (CTEPH)/CTEPD. Prevention: appropriate risk-stratified therapy selection, careful bleeding risk assessment before thrombolysis. Rescue: ECMO, surgical/catheter embolectomy for deteriorating patients.

17. Escalation & De-escalation

Escalate: new/worsening hypotension, rising troponin/lactate, worsening RV function on echo -> reassess category, consider advanced reperfusion, activate/re-engage PERT.

Do not transfer Category E patients to another facility before achieving hemodynamic stabilization.

De-escalate: hemodynamically stable, improving RV function, transition to oral anticoagulation (DOAC preferred), plan outpatient follow-up.

18. ICU Discharge Criteria

Hemodynamically stable off vasopressors, RV function stable/improving, therapeutic and tolerating oral/subcutaneous anticoagulation, no active bleeding, DVT source addressed, follow-up plan for >=1 year post-PE surveillance arranged.

19. Documentation & Medicolegal Checklist

20. Key Guidelines

Creager MA, Barnes GD, Giri J, et al. 2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM/SVN Guideline for the Evaluation and Management of Acute Pulmonary Embolism in Adults. Circulation/JACC. Approved by ACC/AHA Oct 2025; published Feb 19, 2026. — first-ever joint AHA/ACC PE guideline, introduces the A-E Clinical Category system described above.

ESC 2019 Guidelines for diagnosis and management of acute PE (Konstantinides et al.) — prior standard, still widely used internationally.

21. Landmark Trials

• PEITHO trial: tenecteplase + anticoagulation vs anticoagulation alone in intermediate-high-risk PE — reduced hemodynamic decompensation, increased major/intracranial bleeding.
• MOPETT trial: half-dose tPA in "moderate" PE — reduced pulmonary hypertension at follow-up.
• TOPCOAT trial: tenecteplase vs placebo in submassive PE — cardiopulmonary outcome benefit signal at 3 months.
• Chatterjee S et al. meta-analysis: thrombolysis reduces all-cause mortality vs anticoagulation alone but increases major/intracranial bleeding, particularly in patients >65 years.
• Observational ECMO-in-PE data suggesting ~70% survival in severe shock, regardless of concurrent definitive therapy.

22. Controversies

Optimal advanced-therapy selection within Category D (thrombolysis vs catheter-directed vs mechanical thrombectomy vs surgical embolectomy) remains individualized — the 2026 guideline itself notes comparative benefit of surgical embolectomy over thrombolysis is "unclear" beyond ICH-risk reduction. Timing/threshold for transfer to advanced-therapy centers in Category C3-D patients is a 2b/weak recommendation, reflecting genuine practice variation. Role of routine ECMO deployment in severe PE shock lacks RCT evidence. Adoption speed and inter-institutional consistency of the new A-E category system (as opposed to legacy massive/submassive language) will likely take time.

23. References

1. Creager MA, Barnes GD, Giri J, et al. 2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM/SVN Guideline for the Evaluation and Management of Acute Pulmonary Embolism in Adults. J Am Coll Cardiol. 2026;87(13). doi:10.1016/j.jacc.2025.11.005. Also published in Circulation, doi:10.1161/CIR.0000000000001415.
2. Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Respir J. 2019;54:1901647.
3. Wood KE. Massive Pulmonary Embolism. Washington Manual of Critical Care, 4th ed, 2025 (Ch. 6).
4. Piazza G, Goldhaber SZ. The Acutely Decompensated Right Ventricle. Chest. 2005;128(3):1836-1852.
5. Chatterjee S, Chakraborty A, Weinberg I, et al. Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding and intracranial hemorrhage: a meta-analysis. JAMA. 2014;311(23):2414-2421.
6. Sharifi M, Bay C, Skrocki L, et al. Moderate pulmonary embolism treated with thrombolysis (MOPETT). Am J Cardiol. 2013;111(2):273-277.
7. Rivera-Lebron B, McDaniel M, Ahrar K, et al. Diagnosis, treatment and follow up of acute pulmonary embolism: consensus practice from the PERT consortium. Clin Appl Thromb Hemost. 2019;25:1076029619853037.